| HOME >> BIOLOGY >> TECHNOLOGY |
Deferred revenue, net of current
portion 3,320,000 1,621,489
Total liabilities 13,762,049 8,811,527
Commitments and contingencies
Stockholders' equity (deficit)
Series B Convertible Preferred
Stock, $0.01 par value; 1,038,048
issued and outstanding (liquidation
preference of $9 per share, or
$9,342,432 plus accrued but unpaid
dividends) at December 31, 2006 10,380 -
Series A Junior Convertible
Preferred Stock, $0.01 par value;
500,000 issued and outstanding
(liquidation preference of $5 per
share, or $2,500,000) at December
31, 2006 5,000 -
Common stock, $0.01 par value;
20,000,000 and 50,000,000 shares
authorized; 2,726,320 and
10,239,256 shares issued and
outstanding 27,263 102,393
Additional paid-in capital 9,722,273 34,311,892
Accumulated deficit (15,267,284) (18,509,649)
Accumulated other comprehensive
income (loss) - (4,208)
Total stockholders' (deficit)
equity (5,502,368) 15,900,428
Total liabilities and stockholders'
(deficit) equity $ 8,259,681 $ 24,711,955
RESPONSE GENETICS, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended Six Months
June 30, Ended June 30,
2006 2007 2006 2007
Revenue $ 738,150 $ 1,495,618 $ 2,007,125
'/>"/>
SOURCE Response Genetics, Inc.![]() Copyright©2007 PR Newswire. |